Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Relapsed/Refractory CML
NCT00005618Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of arsenic trioxide in chronic myeloid leukemia (CML) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Antileukemic efficacy. Started Feb 2000; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00005618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005618.